Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Blinatumomab demonstrates significant clinical activity in residual ALL

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 4121
Rating:

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

Dr Gökbuget talks to ecancertv at ASH 2014 about her work looking at blinatumomab, an investigational drug known as a bispecific T cell engager antibody construct, in the treatment of acute lymphocytic leukaemia (ALL).

Watch the press conference or read the news story for more.

ecancer's filming at ASH 2014 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation